Paul Licciardi Asia-Pacific Vaccine and Immunotherapy Congress 2026

Abstracts this author is presenting:

• Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia — Welcome Reception & Poster Session